z-logo
Premium
Age‐specific prevalence of HPV 16/18 genotypes in cervical cancer: A systematic review and meta‐analysis
Author(s) -
Hammer Anne,
Rositch Anne,
Qeadan Fares,
Gravitt Patti E,
Blaakaer Jan
Publication year - 2016
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29959
Subject(s) - medicine , cervical cancer , epidemiology , meta analysis , incidence (geometry) , cancer , medline , vaccination , gynecology , oncology , demography , immunology , biology , biochemistry , physics , sociology , optics
The prevalence of HPV16/18 in cervical cancer has been reported to decline with age in some papers. However, whether this decline in proportion of cancers positive for HPV16/18 is consistently observed across studies remains to be elucidated. Thus, the aim of this study was to identify papers reporting data on age‐specific prevalence of HPV16/18 in cervical cancer and to summarize the results. We employed MEDLINE and Embase for a systematic literature search and thereby identified a total of 644 papers published in the period 1999–2015, of which 15 papers, reporting cross‐sectional data, were included for review (11,526 cervical cancers). The prevalence of HPV16/18 in cervical cancer declined significantly with age ( ρ  = −0.83, p  = 0.04) from 74.8% (95% CI 67.6–80.8) in women aged 30–39 years to 56.8% (95% CI 43.9–68.8) in women aged ≥70 years. As the HPV16/18 positive cancers are prevented in fully vaccinated cohorts, the age‐specific epidemiology of cervical cancer is anticipated to change, with a shift in peak incidence rate to older ages. It will be important for integrated vaccination and screening strategies to consider predicted change in the age‐specific epidemiology of cervical cancer.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here